World Health Organization Issues Warning Over Critical Lack of Obesity Injections
Under 10% of people eligible to benefit from weight-loss injections including Wegovy can access them, states the WHO as it issues its initial advice on the medications.
With over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
Per estimates, over two billion could be obese by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant barriers to universal availability to the jabs that can help people shift significant weight, says the organization.
GLP-1 Therapy Supply Crisis
Despite the current most optimistic scenario, the production of these medications would only suffice for approximately 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation calls on governments and firms to expand availability, through approaches like patent sharing.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is due to expire in several countries in 2026.
How Obesity Jabs Function
The injections imitate a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so users eat less.
Individuals usually begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Studies suggests patients may see weight return after a year of discontinuing the drug, as their normal hunger come back.
To be above a healthy weight elevates your likelihood for contracting diseases, such as diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.
